Nine-valent human papillomavirus (HPV) vaccine could prevent 85% of cervical cancers
the ONA take:
According to new research published in the journal Caner Epidemiology, Biomarkers & Prevention, a new nine-valent human papillomavirus (HPV) vaccine after researchers found nine HPV subtypes cause the majority of cervical cancers. Researchers say that 85% or more of precancerous cervical lesions were caused by HPV subtypes 6, 11, 16, 18, 31, 33, 42, 52, and 58. For the study, the researchers analyzed data from three clinical trials studying a quadrivalent HPV vaccine that protects against subtypes 6, 11, 16, and 18. They identified 2,507 women aged 15 to 45 diagnosed with cervical intraepithelial neoplasia 1(CIN1), CIN2, CIN3, or adenocarcinoma in-situ (AIS).
With the nine HPV subtypes included in the investigational HPV vaccine, which is being developed by Merck and under review with the U.S. Food and Drug Administration, in mind, the researchers estimated the number of precancerous lesions triggered by those nine HPV subtypes in the 2,507 women. After adjustments, they found that seven of the nine HPV subtypes included in the vaccine were present in approximately 55% of CIN1, 78% of CIN2, 91% of CIN3, and 100% of AIS lesions. Some women were infected with multiple HPV subtypes.
Researchers found nine HPV subtypes cause the majority of cervical cancers
Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
"We wanted to study how many cervical precancers could potentially be prevented by an investigational nine-valent HPV vaccine that provides protection against the HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58," said Elmar A. Joura, MD, an associate professor of gynecology at the Medical University of Vienna in Austria. "Approximately 85 percent or more of precancerous lesions of the cervix were attributed to the nine HPV types covered in the vaccine; therefore, if nine-valent HPV vaccination programs are effectively implemented, the majority of these lesions could be prevented.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|